Health Care · Biological Products, (No Diagnostic Substances) · NYSE · CIK 1006281 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.27Day −2.58%Mkt cap $183M1Y +55.5%Off 52W high −28.8%Vol (1Y) 64.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,312 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.6% of sh out |
| Days to cover6.6d |
| 13F net flow (QoQ)−2.20% |
| Top-10 13F concentration76.9% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$76.4M |
| Earnings (TTM)$15.3M |
| ROE−14.4% |
| Net margin−12.5% |
| ROIC−15.2% |
| Sales growth 3Y3.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+26.1% |
| 1Y+55.5% |
| 3Y+41.9% |
| 5Y+45.5% |
| 10Y−64.9% |
| Since incept. (ann.)−9.8% |
Total return through 2026-07-29 · series begins 2005-06-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)64.2% |
| Ann. volatility (3Y)67.5% |
| Sharpe (1Y)0.98 |
| Sharpe (3Y)0.51 |
| Max drawdown (1Y)−39.7% |
| Max drawdown (3Y)−56.0% |
| Beta (3Y vs SPY)0.14 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 3.6M | $8M | 4.49% | −0.8% |
| MAK CAPITAL ONE LLC | 3.5M | $8M | 4.40% | new |
| RENAISSANCE TECHNOLOGIES LLC | 1.2M | $3M | 1.52% | −3.0% |
| STATE STREET CORP | 972,815 | $2M | 1.21% | +66.2% |
| NORTHERN TRUST CORP | 885,448 | $2M | 1.10% | +2.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 865,298 | $2M | 1.07% | +4.2% |
| Stratos Wealth Partners, LTD. | 500,000 | $1M | 0.62% | +0.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 432,485 | $938,492 | 0.54% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | $0.22 | — | $33.8M | +233.7% |
| 2025-12-31 | 2026-03-18 | — | — | $9.1M | −49.9% |
| 2025-09-30 | 2025-11-13 | $0.03 | +0.0% | $17.9M | −0.6% |
| 2025-06-30 | 2025-08-14 | $0.00 | — | $15.7M | +16.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Single Operating 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
